Is IP Group PLC (LON:IPO) a Buy or a Sell? Numis Gives ‘Under Review’; Dova Pharmaceuticals (DOVA) Sellers Increased By 5.75% Their Shorts

Dova Pharmaceuticals Incorporated (NASDAQ:DOVA) had an increase of 5.75% in short interest. DOVA’s SI was 2.62 million shares in February as released by FINRA. Its up 5.75% from 2.47 million shares previously. With 46,300 avg volume, 57 days are for Dova Pharmaceuticals Incorporated (NASDAQ:DOVA)’s short sellers to cover DOVA’s short positions. The stock decreased 2.06% or $0.62 during the last trading session, reaching $29.49. About 59,212 shares traded. Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) has 0.00% since February 9, 2017 and is . It has underperformed by 16.70% the S&P500.

In analysts report sent to clients and investors by Numis on Friday, 9 February, IP Group PLC (LON:IPO)‘s stock had its ‘Under Review’ rating maintained.

IP Group Plc is a private equity and venture capital firm specializing in seed, early stage, start-up, incubation, and mature financing. The company has market cap of 1.25 billion GBP. The firm also provides seed capital financing to spin out companies from the universities. It has a 19.97 P/E ratio. It seeks to invest in the life sciences, physical sciences, energy & renewables, medical equipment and supplies, healthcare, technology, cleantech, intellectual property, pharmaceuticals & biotechnology, information technology & communications, and chemicals & materials.

The stock decreased 0.67% or GBX 0.8 during the last trading session, reaching GBX 117.8. About 655,337 shares traded. IP Group Plc (LON:IPO) has 0.00% since February 9, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 4 analysts covering IP Group PLC (LON:IPO), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. IP Group PLC has GBX 358 highest and GBX 169 lowest target. GBX 220.67’s average target is 87.33% above currents GBX 117.8 stock price. IP Group PLC had 30 analyst reports since August 5, 2015 according to SRatingsIntel. Stifel Nicolaus initiated the shares of IPO in report on Thursday, September 3 with “Buy” rating. The firm has “Buy” rating by Numis Securities given on Thursday, March 10. The firm has “Buy” rating by Numis Securities given on Thursday, September 29. Stifel Nicolaus maintained IP Group Plc (LON:IPO) on Tuesday, February 14 with “Buy” rating. The company was maintained on Thursday, May 12 by Numis Securities. The rating was maintained by Jefferies on Wednesday, June 21 with “Buy”. The rating was maintained by Beaufort Securities with “Buy” on Monday, August 17. The stock of IP Group Plc (LON:IPO) has “Buy” rating given on Wednesday, January 13 by Beaufort Securities. The firm earned “Buy” rating on Friday, May 13 by Beaufort Securities. The stock of IP Group Plc (LON:IPO) has “Buy” rating given on Tuesday, January 12 by Numis Securities.

Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia diseases. The company has market cap of $756.49 million. The Company’s drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver diseases. It currently has negative earnings.